Figure 2. Univariate survival analysis of the estrogen receptor-positive (ER+)/progesterone receptor (PR) low expression patients and the ER+/PR high expression patients with disease-free survival (DFS), overall survival (OS) and breast cancer specific survival (BCSS). (A) DFS, (B) OS, and (C) BCSS. The figure show that low expression of PR expression was associated with significantly poorer DFS, OS, and BCSS in ER+ patients treated with any endocrine therapy.
